EUVIMEDEUVIMED entdecken
Crossref

IDENTIFICATION OF PARP-1 INHIBITORS AGAINST BREAST CANCER USING IN SILICO REPURPOSING OF FDA APPROVED DRUGS: DOCKING BASED APPROACH, MM/GBSA AND ADME ANALYSIS

Bhatnagar A, Nath V, Kumar V

Bulletin of Pharmaceutical Research · 2024-12 · 14 (3) · 1-8

DOI: 10.21276/bpr.2024.14.3.1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bulletin of Pharmaceutical Research, 2024-12. Verfasst von Bhatnagar A und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug discovery approaches have been time consuming and require huge monetary investments. The repurposing of already existing drugs is a promising approach for the faster and cost-effective drug discovery against various diseases. Cancer, being a heterogenous disease, requires special attention and breast cancer becomes a medical emergency, as it is the most diagnosed cancer among women associated with higher chances of relapse and recurrence. Targeted therapies overcome the toxic effects of conventional cancer therapies, and the development of new targeted therapies are the need of the hour due to the problems of acquired resistance, and deteriorating cancer scenario. PARP-1 emerges an attractive target for drug discovery against breast cancer due to its vital role in DNA repair. Therefore, the aim of the present work was to repurpose existing FDA approved drugs targeting PARP-1 inhibitors as anti-breast cancer agents. A three-tier virtual screening followed by binding energy analysis, was performed to find the FDA approved drugs exhibiting good and stable binding characteristics with PARP-1. Further, a comparative analysis of the in silico ADME profile of the drugs was carried out. Combined results of the in silico analysis were used for selecting best hits against PARP-1. Two best hits, Candesartan and Mycophenolic acid, were selected and the structural features of both the compounds matched with PARP-1 selective inhibitor, Olaparib. Further, in vitro and in vivo validation of the in silico results is warranted for assessing the potential of these compounds as repurposed PARP-1 inhibitors.

Zitieren

APA

A, B., V, N., & V, K. (2024). IDENTIFICATION OF PARP-1 INHIBITORS AGAINST BREAST CANCER USING IN SILICO REPURPOSING OF FDA APPROVED DRUGS: DOCKING BASED APPROACH, MM/GBSA AND ADME ANALYSIS. Bulletin of Pharmaceutical Research, 14(3), 1-8. https://doi.org/10.21276/bpr.2024.14.3.1

Vancouver

A B, V N, V K. IDENTIFICATION OF PARP-1 INHIBITORS AGAINST BREAST CANCER USING IN SILICO REPURPOSING OF FDA APPROVED DRUGS: DOCKING BASED APPROACH, MM/GBSA AND ADME ANALYSIS. Bulletin of Pharmaceutical Research. 2024;14(3):1-8. doi:10.21276/bpr.2024.14.3.1

BibTeX
@article{A2024,
  author = {A, Bhatnagar and V, Nath and V, Kumar},
  title = {IDENTIFICATION OF PARP-1 INHIBITORS AGAINST BREAST CANCER USING IN SILICO REPURPOSING OF FDA APPROVED DRUGS: DOCKING BASED APPROACH, MM/GBSA AND ADME ANALYSIS},
  journal = {Bulletin of Pharmaceutical Research},
  year = {2024},
  volume = {14},
  number = {3},
  pages = {1--8},
  doi = {10.21276/bpr.2024.14.3.1}
}
Kostenlos starten →